Related references
Note: Only part of the references are listed.Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials
Y. Zhou et al.
DIABETIC MEDICINE (2021)
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial
Jeroen Koomen et al.
DIABETES OBESITY & METABOLISM (2021)
New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction
Hiddo J. L. Heerspink et al.
KIDNEY INTERNATIONAL (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Diabetic kidney disease in type 2 diabetes: a review of pathogenic mechanisms, patient-related factors and therapeutic options
Louise Woodhams et al.
PEERJ (2021)
SONAR: Do a New Design and Statistically Significant Results Translate to Reliability?
Michael Walsh
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review
Li Zhang et al.
WORLD JOURNAL OF DIABETES (2020)
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Hiddo J. L. Heerspink et al.
LANCET (2019)
Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy
Chih-Wei Lin et al.
CLINICAL THERAPEUTICS (2018)
Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight
Jeroen V. Koomen et al.
DIABETES OBESITY & METABOLISM (2018)
Diabetic nephropathy: newer therapeutic perspectives
Krishna C. Keri et al.
JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES (2018)
Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial
David J. Webb et al.
DRUGS IN R&D (2017)
Diabetic Kidney Disease Challenges, Progress, and Possibilities
Radica Z. Alicic et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy
Michelle J. Pena et al.
DIABETES OBESITY & METABOLISM (2017)
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers
Bauke Schievink et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2016)
Relationship Between Dyslipidemia and Albuminuria in Hypertensive Adults A Nationwide Population-Based Study
Sung-Ho Lee et al.
MEDICINE (2016)
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy
Donald E. Kohan et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Endothelin-receptor antagonists for diabetic nephropathy: A meta-analysis
Wenming Yuan et al.
NEPHROLOGY (2015)
Endothelin Blockade in Diabetic Kidney Disease
Lidia Anguiano et al.
JOURNAL OF CLINICAL MEDICINE (2015)
Endothelin Antagonists in Diabetic Nephropathy: Back to Basics
Kiran Chandrashekar et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy
Dick de Zeeuw et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Update on Potential Drugs for the Treatment of Diabetic Kidney Disease
Brian Shepler et al.
CLINICAL THERAPEUTICS (2012)
The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial
A. Rafnsson et al.
DIABETOLOGIA (2012)
Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD)
Dennis L. Andress et al.
LIFE SCIENCES (2012)
Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy
Donald E. Kohan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Avosentan for Overt Diabetic Nephropathy
Johannes F. E. Mann et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria
Rene R. Wenzel et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)